XBiotech Inc (NASDAQ:XBIT) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued on Saturday.

Other equities analysts also recently issued reports about the company. Zacks Investment Research upgraded XBiotech from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a research report on Saturday, May 20th. Noble Financial reiterated a “hold” rating and set a $13.00 price objective on shares of XBiotech in a research report on Friday, April 21st. Finally, Stifel Nicolaus upgraded XBiotech from a “hold” rating to a “buy” rating in a research report on Saturday, June 3rd.

Shares of XBiotech (NASDAQ XBIT) traded down 66.03% during trading on Friday, hitting $3.20. The stock had a trading volume of 1,884,100 shares. XBiotech has a one year low of $2.77 and a one year high of $25.00. The firm’s market cap is $112.93 million. The firm’s 50-day moving average is $9.21 and its 200-day moving average is $12.26.

TRADEMARK VIOLATION NOTICE: This article was first posted by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/06/10/xbiotech-inc-xbit-rating-lowered-to-strong-sell-at-valuengine.html.

Several institutional investors have recently modified their holdings of the company. American International Group Inc. boosted its stake in shares of XBiotech by 7.1% in the first quarter. American International Group Inc. now owns 10,764 shares of the biopharmaceutical company’s stock valued at $177,000 after buying an additional 709 shares during the last quarter. Teachers Advisors LLC boosted its stake in shares of XBiotech by 6.8% in the fourth quarter. Teachers Advisors LLC now owns 27,619 shares of the biopharmaceutical company’s stock valued at $280,000 after buying an additional 1,759 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of XBiotech by 6.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 64,203 shares of the biopharmaceutical company’s stock valued at $1,059,000 after buying an additional 3,762 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of XBiotech by 4.9% in the first quarter. Geode Capital Management LLC now owns 152,318 shares of the biopharmaceutical company’s stock valued at $2,511,000 after buying an additional 7,066 shares during the last quarter. Finally, A.R.T. Advisors LLC purchased a new stake in shares of XBiotech during the fourth quarter valued at approximately $103,000. Institutional investors and hedge funds own 10.14% of the company’s stock.

XBiotech Company Profile

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for XBiotech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech Inc and related companies with MarketBeat.com's FREE daily email newsletter.